Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: REGN

Regeneron Pharmaceuticals, Inc.

Healthcare | Biotechnology
$689.17 -62.40 (-8.30%) as of 2026-07-14 15:22 UTC
Market Cap$74.8B
EPS (TTM)$41.48

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a $74.8B biotechnology company trading at $689.17 (−8.3% today) — 16.6× trailing earnings, yielding 0.49%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 15:22 UTC.

52-Week Range
Low $476.49High $821.11

What Regeneron Pharmaceuticals, Inc. does

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. The company's product portfolio and product candidates in development are designed to address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Summarized from Regeneron Pharmaceuticals, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$689.17
Change (1D)-62.40 (-8.30%)
Market cap$74.8B
52-week range$476.49 – $821.11
Valuation
P/E (TTM)16.61×
EV/EBITDA17.90×
EPS (TTM)$41.48
Dividend yield0.49%
Price/book2.39×
Return on equity14.41%
Debt/equity0.06
Returns
52-week return+44.6%
Revenue, margins & earnings
FY2021 Net income: $8.08BFY2021 Taxes & interest: $872MFY2021 Operating costs: $7.12B$16.1BFY2021FY2022 Net income: $4.34BFY2022 Taxes & interest: $400MFY2022 Operating costs: $7.43B$12.2BFY2022FY2023 Net income: $3.95BFY2023 Operating costs: $9.07B$13.1BFY2023FY2024 Revenue: $14.2B — margin split not shown (non-operating gains)$14.2BFY2024FY2025 Revenue: $14.3B — margin split not shown (non-operating gains)$14.3BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-07
  • 2026-07-07RYAN ARTHUR FSELL-200$130.0K
  • 2026-05-04RYAN ARTHUR FSELL-15$10.5K
  • 2026-05-04RYAN ARTHUR FSELL-5$3.5K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC9,075,117$7.00B+0.3%
  • BlackRock, Inc.8,155,020$6.30B-6.7%
  • VANGUARD CAPITAL MANAGEMENT LLC6,654,913$5.14BNEW
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.

What is REGN's valuation?

REGN trades at $689.17, 16.61× trailing earnings, 17.90× EV/EBITDA, as of 2026-07-14. It carries a 0.49% dividend yield.

When did REGN last file with the SEC?

Regeneron Pharmaceuticals, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-04-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 15:22 UTC. This page is also available as JSON at /api/data?ticker=REGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for REGN and 3,500+ tickers.

Create a free account — keep REGN
For your agent
GET /api/data?ticker=REGN

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt